ENVBEnveric Biosciences, Inc.

Nasdaq enveric.com


$ 0.53 $ -0.01 (-0.94 %)    

Tuesday, 16-Jul-2024 15:59:50 EDT
QQQ $ 496.22 $ 0.19 (0.04 %)
DIA $ 409.69 $ 7.30 (1.81 %)
SPY $ 564.93 $ 3.33 (0.59 %)
TLT $ 94.14 $ 1.31 (1.41 %)
GLD $ 228.28 $ 4.46 (1.99 %)
$ 0.5349
$ 0.51
$ 0.00 x 0
$ 0.00 x 0
$ 0.51 - $ 0.54
$ 0.41 - $ 3.90
444,477
na
2.14M
$ 1.49
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-26-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 03-31-2022 12-31-2021 10-K
11 11-13-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 04-01-2021 12-31-2020 10-K
15 11-16-2020 09-30-2020 10-Q
16 08-14-2020 06-30-2020 10-Q
17 05-15-2020 03-31-2020 10-Q
18 03-25-2020 12-31-2019 10-K
19 11-08-2019 09-30-2019 10-Q
20 08-14-2019 06-30-2019 10-Q
21 05-14-2019 03-31-2019 10-Q
22 03-26-2019 12-31-2018 10-K
23 11-14-2018 09-30-2018 10-Q
24 08-14-2018 06-30-2018 10-Q
25 05-15-2018 03-31-2018 10-Q
26 04-02-2018 12-31-2017 10-K
27 11-13-2017 09-30-2017 10-Q
28 08-14-2017 06-30-2017 10-Q
29 05-12-2017 03-31-2017 10-Q
30 03-31-2017 12-31-2016 10-K
31 11-14-2016 09-30-2016 10-Q
32 08-12-2016 06-30-2016 10-Q
33 05-16-2016 03-31-2016 10-Q
34 11-23-2015 09-30-2015 10-Q
35 08-14-2015 06-30-2015 10-Q
36 05-14-2015 03-31-2015 10-Q
37 03-31-2015 12-31-2014 10-K
38 11-13-2014 09-30-2014 10-Q
39 08-11-2014 06-30-2014 10-Q
40 05-07-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted...

 aries-science--technology-and-enveric-biosciences-announce-licensing-agreement-eligible-to-receive-milestone-payments-of-up-to-61m-on-future-sales-if-all-conditions-met

-SEC Filing

 new-patented-psychedelic-drug-brings-hope-for-brain-disorder-therapies

Enveric Biosciences has been granted a U.S. patent for EB-002, enhancing protection for treatments targeting brain neurological...

 enveric-biosciences-elevates-eb-003-to-lead-development-candidate-provides-strategic-outlook-and-pipeline-update

EB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health disorders without the hallucinogenic effect...

Core News & Articles

https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after...

 on-may-21-enveric-biosciences-received-letter-from-nasdaq-notifying-co-that-it-regained-compliance-with-minimum-stockholders-equity-requirement

- SEC Filing

 psychedelics-inspired-meds-for-depression-anxiety-addiction-producer-trims-q1-net-loss-yoy-increases-cash-on-hand

Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe ...

 enveric-biosciences-q1-2024-gaap-eps-061-beats-078-estimate

Enveric Biosciences (NASDAQ:ENVB) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $...

 cannabinoids-with-chemotherapy-for-breast-cancer-psychedelics-biotech-inks-61m-license-deal-for-patented-methods

The news of the licensee deal comes on the heels of the DEA's move to reschedule marijuana, one source of cannabinoids, as ...

Core News & Articles

https://www.marijuanamoment.net/fda-expert-committee-will-review-mdma-assisted-therapy-for-ptsd-next-month/The Food and Drug Ad...

 why-ulta-beauty-shares-are-trading-lower-by-around-14-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the ...